The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...
Adding a minimally invasive laser procedure to immunotherapy achieved dramatically improved survival in a small study of patients with recurrent high-grade astrocytoma, an aggressive brain cancer with ...
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results